News

Home  >  News > Iproteos wins the Expoquimia R+D+I Award in the Biotechnology category

Iproteos wins the Expoquimia R+D+I Award in the Biotechnology category

Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.

Ernest Giralt i Teresa Tarragó, fundadors d'Iproteos, durant l'acte del lliurament del premi.

09/10/2014

Recerca

The Catalan biotech Iproteos —a spin-off of the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) located at the Barcelona Science Park (PCB)— has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia. Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona. The company, which expects to begin clinical trials of the compound in 2016, emerged from the transfer of a technology developed at UB and IRB Barcelona, with the strategic participation of the Bosch i Gimpera Foundation (FBG). It is important to remember that the University of Barcelona (UB) participated in the fair Expoquimia 2014 in which the Barcelona Knowledge Campus (BKC), one of UB’s campus of International excellence, presented the BKC Chemistry.

 

Share this at:
| More |
  • Follow us:
  • Button to access University of Barcelona's Facebook profile
  • Button to access University of Barcelona's Twitter profile
  • ??? peu.google.alt ???
  • Button to access University of Barcelona's Youtube profile
  • Button to access University of Barcelona's RSS
Member of: Two Campuses of International Excellence logo del leru - League of European Research Universities logo del bkc - campus excel·lència logo del health universitat de barcelona campus

© Universitat de Barcelona